Skip to main content
Fig. 8 | BMC Medicine

Fig. 8

From: SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment

Fig. 8

OH2 treatment polarized macrophages to M1 for tumour killing in vivo, and the SIRPα antibody combined with OH2 therapy reshapes the TME and activates a more comprehensive anti-tumour immune response. The introduction of the SIRPα antibody can accelerate cellular reconstitution of TME and induce a specific antitumour immune response through an earlier innate immune response

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us